Robert Alarcón Cedeño
Robert Alarcón Cedeño has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Luis Mariano de la Torre Fonseca
Hospital Comandante Manuel Fajardo, Cuba
5 shared publications - Rodrigo Estévez-Loureiro
Department of Cardiology. University Hospital Alvaro Cunqueiro, Vigo, Spain. Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Fundación Biomédica Galicia Sur, Servizo Galego de Saude, University of Vigo, Vigo, Spain
5 shared publications - Manuel Barreiro-Pérez
Cardiology Department, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute, Vigo, Spain
4 shared publications - Pablo Juan-Salvadores
University Hospital of Vigo, Espanha; Galicia Sur Health Research Institute, Espanha
4 shared publications - Diego Milton Pulla Quezada
Institute of Cardiovascular Health, Equador
3 shared publications - Juan Díaz-Heredia
Universidad Catolica de Santiago de Guayaquil, Equador
3 shared publications
Latest Publications
- Open Access
- 27 June 2025
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 6 (2) , 75-82
Tratamiento farmacológico de pacientes con insuficiencia cardíaca crónica. Subanálisis de un registro ecuatoriano
Introduction. Introduction. In Ecuador, there is limited data on the treatment of patients with heart failure (HF). Objective. This study aimed to determine the rate of use of prognosis-modifying drugs and their association with prognosis. Materials and methods. A retrospective observational study was conducted on patients with chronic HF included in the “Los Ceibos” registry between January 2017 and December 2022. Patients were followed for a median of 2.28 years (interquartile range [IQR]: 1.25-3.49). Results. A total of 711 patients diagnosed with HF were included. Among them, 82.7% (n=588) received angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor–neprilysin inhibitors (ARNIs); 82.3% (n=585) received beta-blockers (BBs); and 51.3% (n=365) were treated with mineralocorticoid receptor antagonists (MRAs). Among patients with HFrEF, those receiving triple therapy (ACEI/ARB/ARNI + BB + MRA) had lower all-cause mortality compared to other groups (38.8%, log-rank p=0.014). In patients with Heart Failure with preserved Ejection Fraction (HFpEF), no mortality differences were observed according to the number of medications used (log-rank p=0.720). MRA use was not associated with a prognostic benefit in HFpEF (p>0.05). Patients receiving triple therapy with ARNI + BB + MRA had better survival during follow-up compared to any other drug combination (log-rank p=0.027). Conclusions. A high rate of ACEI/ARB/ARNI and BB use was observed. The use of triple therapy, particularly the combination of ARNI + BB + MRA, was associated with improved prognosis in patients with HFrEF over a four-year follow-up period. No prognostic benefit of MRA use was observed in patients with HFpEF.
- 27 June 2025
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 6 (2) , 75-82
Open AccessTratamiento farmacológico de pacientes con insuficiencia cardíaca crónica. Subanálisis de un registro ecuatoriano
Introduction. Introduction. In Ecuador, there is limited data on the treatment of patients with heart failure (HF). Objective. This study aimed to determine the rate of use of prognosis-modifying drugs and their association with prognosis. Materials and methods. A retrospective observational study was conducted on patients with chronic HF included in the “Los Ceibos” registry between January 2017 and December 2022. Patients were followed for a median of 2.28 years (interquartile range [IQR]: 1.25-3.49). Results. A total of 711 patients diagnosed with HF were included. Among them, 82.7% (n=588) received angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor–neprilysin inhibitors (ARNIs); 82.3% (n=585) received beta-blockers (BBs); and 51.3% (n=365) were treated with mineralocorticoid receptor antagonists (MRAs). Among patients with HFrEF, those receiving triple therapy (ACEI/ARB/ARNI + BB + MRA) had lower all-cause mortality compared to other groups (38.8%, log-rank p=0.014). In patients with Heart Failure with preserved Ejection Fraction (HFpEF), no mortality differences were observed according to the number of medications used (log-rank p=0.720). MRA use was not associated with a prognostic benefit in HFpEF (p>0.05). Patients receiving triple therapy with ARNI + BB + MRA had better survival during follow-up compared to any other drug combination (log-rank p=0.027). Conclusions. A high rate of ACEI/ARB/ARNI and BB use was observed. The use of triple therapy, particularly the combination of ARNI + BB + MRA, was associated with improved prognosis in patients with HFrEF over a four-year follow-up period. No prognostic benefit of MRA use was observed in patients with HFpEF.
- Open Access
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3)
Survival in Patients with Brugada Phenocopy. Case Series
Introduction Brugada phenocopy (BP) refers to a situation in which the characteristic electrocardiographic patterns of Brugada syndrome (BS) are temporarily manifested, which are indistinguishable from the type 1 (coved) and 2 (saddleback) patterns of BS. Several additional criteria must be considered for an accurate diagnosis. These include the presence of an identifiable underlying cause, regression of the pattern once this cause is corrected, low pretest probability of BS, a negative result of a pharmacological induction test, and a negative genetic [...] Introduction Brugada phenocopy (BP) refers to a situation in which the characteristic electrocardiographic patterns of Brugada syndrome (BS) are temporarily manifested, which are indistinguishable from the type 1 (coved) and 2 (saddleback) patterns of BS. Several additional criteria must be considered for an accurate diagnosis. These include the presence of an identifiable underlying cause, regression of the pattern once this cause is corrected, low pretest probability of BS, a negative result of a pharmacological induction test, and a negative genetic
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3)
Open AccessSurvival in Patients with Brugada Phenocopy. Case Series
Introduction Brugada phenocopy (BP) refers to a situation in which the characteristic electrocardiographic patterns of Brugada syndrome (BS) are temporarily manifested, which are indistinguishable from the type 1 (coved) and 2 (saddleback) patterns of BS. Several additional criteria must be considered for an accurate diagnosis. These include the presence of an identifiable underlying cause, regression of the pattern once this cause is corrected, low pretest probability of BS, a negative result of a pharmacological induction test, and a negative genetic [...] Introduction Brugada phenocopy (BP) refers to a situation in which the characteristic electrocardiographic patterns of Brugada syndrome (BS) are temporarily manifested, which are indistinguishable from the type 1 (coved) and 2 (saddleback) patterns of BS. Several additional criteria must be considered for an accurate diagnosis. These include the presence of an identifiable underlying cause, regression of the pattern once this cause is corrected, low pretest probability of BS, a negative result of a pharmacological induction test, and a negative genetic
- Open Access
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3)
Sobrevida em Pacientes com Fenocópia de Brugada. Série de Casos
Introdução A fenocópia de Brugada (FB) se refere a uma situação na qual os padrões eletrocardiográficos característicos da síndrome de Brugada (SB) são temporariamente manifestados, os quais são indistinguíveis dos padrões tipo 1 (coberto) e 2 (sela) da SB. Vários critérios adicionais devem ser considerados para um diagnóstico preciso. Estes incluem a presença de uma causa subjacente identificável, regressão do padrão uma vez que esta causa é corrigida, baixa probabilidade pré-teste de SB, um resultado negativo de um teste de [...] Introdução A fenocópia de Brugada (FB) se refere a uma situação na qual os padrões eletrocardiográficos característicos da síndrome de Brugada (SB) são temporariamente manifestados, os quais são indistinguíveis dos padrões tipo 1 (coberto) e 2 (sela) da SB. Vários critérios adicionais devem ser considerados para um diagnóstico preciso. Estes incluem a presença de uma causa subjacente identificável, regressão do padrão uma vez que esta causa é corrigida, baixa probabilidade pré-teste de SB, um resultado negativo de um teste de
- 1 March 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (3)
Open AccessSobrevida em Pacientes com Fenocópia de Brugada. Série de Casos
Introdução A fenocópia de Brugada (FB) se refere a uma situação na qual os padrões eletrocardiográficos característicos da síndrome de Brugada (SB) são temporariamente manifestados, os quais são indistinguíveis dos padrões tipo 1 (coberto) e 2 (sela) da SB. Vários critérios adicionais devem ser considerados para um diagnóstico preciso. Estes incluem a presença de uma causa subjacente identificável, regressão do padrão uma vez que esta causa é corrigida, baixa probabilidade pré-teste de SB, um resultado negativo de um teste de [...] Introdução A fenocópia de Brugada (FB) se refere a uma situação na qual os padrões eletrocardiográficos característicos da síndrome de Brugada (SB) são temporariamente manifestados, os quais são indistinguíveis dos padrões tipo 1 (coberto) e 2 (sela) da SB. Vários critérios adicionais devem ser considerados para um diagnóstico preciso. Estes incluem a presença de uma causa subjacente identificável, regressão do padrão uma vez que esta causa é corrigida, baixa probabilidade pré-teste de SB, um resultado negativo de um teste de
- 24 February 2025
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 164 (5) , 226-231
Percutaneous gastric embolization for obesity: A prospective mid-term outcomes study
- 24 February 2025
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 164 (5) , 226-231
Percutaneous gastric embolization for obesity: A prospective mid-term outcomes study
- 26 November 2024
- Published by Elsevier in Medicina Clinica
- Vol. 164 (5) , 226-231
Embolización gástrica percutánea en pacientes con obesidad: un estudio prospectivo de resultados a medio plazo
- 26 November 2024
- Published by Elsevier in Medicina Clinica
- Vol. 164 (5) , 226-231
Embolización gástrica percutánea en pacientes con obesidad: un estudio prospectivo de resultados a medio plazo
- Open Access
- 26 March 2024
- Published by Federacion Argentina de Cardiología in Revista de la Federación Argentina de Cardiología
- Vol. 53 (1) , 32-37
Predictores de complicaciones cardiovasculares en pacientes geriátricos con síndrome coronario agudo
Introduction: acute coronary syndromes (ACS) complications have an adverse impact on patientmorbidity and mortality, and are related to certain risk factors. Aim: to determine the predictors of cardiovascular complications in geriatric patients with ACS. Materials and methods: cohort study, retrospective and cross-sectional study in 827 patients over 60 years of age, admitted to the Hospital Docente Clínico Quirúrgico Comandante Manuel Fajardo, between 2016 - 2021. Results: The average age was 76.59 years and 58.89% of the patients were female. Hypertensive patients (88.1%) and a history of ischemic heart disease (62.3%) prevailed. There were 199 patients (24.06%) with cardiovascular complications, associated with a history of ischemic heart disease (p=0.002, OR>1); while hemodynamic complications (73.87%) were associated with female sex, history of HTN and unstable angina (p1). The risk of cardiovascular complications was increased in diabetics (p<0.05) and the risk of hemodynamic complications was also increased in women, patients with a history of diabetes mellitus and HTN (p<0.05). Conclusions: in ACS, diabetes mellitus is a predictor of cardiovascular complications; and female sex, diabetes mellitus and hypertension are predictors of hemodynamic complications.
- 26 March 2024
- Published by Federacion Argentina de Cardiología in Revista de la Federación Argentina de Cardiología
- Vol. 53 (1) , 32-37
Open AccessPredictores de complicaciones cardiovasculares en pacientes geriátricos con síndrome coronario agudo
Introduction: acute coronary syndromes (ACS) complications have an adverse impact on patientmorbidity and mortality, and are related to certain risk factors. Aim: to determine the predictors of cardiovascular complications in geriatric patients with ACS. Materials and methods: cohort study, retrospective and cross-sectional study in 827 patients over 60 years of age, admitted to the Hospital Docente Clínico Quirúrgico Comandante Manuel Fajardo, between 2016 - 2021. Results: The average age was 76.59 years and 58.89% of the patients were female. Hypertensive patients (88.1%) and a history of ischemic heart disease (62.3%) prevailed. There were 199 patients (24.06%) with cardiovascular complications, associated with a history of ischemic heart disease (p=0.002, OR>1); while hemodynamic complications (73.87%) were associated with female sex, history of HTN and unstable angina (p1). The risk of cardiovascular complications was increased in diabetics (p<0.05) and the risk of hemodynamic complications was also increased in women, patients with a history of diabetes mellitus and HTN (p<0.05). Conclusions: in ACS, diabetes mellitus is a predictor of cardiovascular complications; and female sex, diabetes mellitus and hypertension are predictors of hemodynamic complications.
- Open Access
- 5 March 2024
- Published by Springer Nature in Research Square
Percutaneous Gastric Embolisation in Obese Patients: A Prospective Study of Mid-Term Outcomes
Introduction Obesity represents one of the most pressing public health challenges that needs to be solved globally, with serious health implications. Percutaneous gastric embolisation has emerged as a promising technique in the management of obesity. Objective This study aims to evaluate the relationship between endovascular procedure and weight loss in obese patients. In addition, to determine the complications related to percutaneous gastric embolisation in these patients. Design: Prospective longitudinal cohort study during the period from 1 January to 31 December 2022 and received treatment with percutaneous gastric embolisation Setting: This study includes patients admitted to the Haemodynamics Service of the Cardiovascular Health Institute during the year 2022. Participants: This study includes 15 patients diagnosed with grade III obesity who met the following criteria: patients ≥ 18 years with a diagnosis of obesity as determined by a body mass index greater than 30 kg/m2 and less than 40 kg/m 2, admitted between January to December 2022, and patients with a diagnosis of obesity with BMI > 40 kg/m2 with contraindication or refusal of bariatric. Main Outcome(s) and Measure(s): This is one of the largest studies in percutaneous gastric embolisation an obese population, while assessing the sustainability of weight loss outcomes. The main findings of the study can be summarised as follows: a) The procedure is safe without major complications, ulcers or gastric ischaemia, b) These technique achieves significant weight loss that is maintained over time. Results 86.7% were successful. Treated patients experienced significant weight loss when comparing baseline weight (101.2 ± 23.0 SE = 5.9) with weight at 6 months after the interventional procedure (91.5 ± 19.8, SE = 5.1) t(14) = 5.3, p < 0.001, d = 0.45. Especially males (106.7 ± 18.4, p = 0.01). No major vascular complications, gastric ulcer or ischaemia, or abdominal symptoms were documented in any of the patients included in the study. Only 6 patients (40%) presented with epigastralgia, 9 (60%) with nausea and 3 (20%) with vomiting. Conclusions Percutaneous gastric embolisation is an effective and safe procedure to reduce body mass index with a high success rate, well tolerated by obese patients, without major complications, whose results are maintained over time.
- 5 March 2024
- Published by Springer Nature in Research Square
Open AccessPercutaneous Gastric Embolisation in Obese Patients: A Prospective Study of Mid-Term Outcomes
Introduction Obesity represents one of the most pressing public health challenges that needs to be solved globally, with serious health implications. Percutaneous gastric embolisation has emerged as a promising technique in the management of obesity. Objective This study aims to evaluate the relationship between endovascular procedure and weight loss in obese patients. In addition, to determine the complications related to percutaneous gastric embolisation in these patients. Design: Prospective longitudinal cohort study during the period from 1 January to 31 December 2022 and received treatment with percutaneous gastric embolisation Setting: This study includes patients admitted to the Haemodynamics Service of the Cardiovascular Health Institute during the year 2022. Participants: This study includes 15 patients diagnosed with grade III obesity who met the following criteria: patients ≥ 18 years with a diagnosis of obesity as determined by a body mass index greater than 30 kg/m2 and less than 40 kg/m 2, admitted between January to December 2022, and patients with a diagnosis of obesity with BMI > 40 kg/m2 with contraindication or refusal of bariatric. Main Outcome(s) and Measure(s): This is one of the largest studies in percutaneous gastric embolisation an obese population, while assessing the sustainability of weight loss outcomes. The main findings of the study can be summarised as follows: a) The procedure is safe without major complications, ulcers or gastric ischaemia, b) These technique achieves significant weight loss that is maintained over time. Results 86.7% were successful. Treated patients experienced significant weight loss when comparing baseline weight (101.2 ± 23.0 SE = 5.9) with weight at 6 months after the interventional procedure (91.5 ± 19.8, SE = 5.1) t(14) = 5.3, p < 0.001, d = 0.45. Especially males (106.7 ± 18.4, p = 0.01). No major vascular complications, gastric ulcer or ischaemia, or abdominal symptoms were documented in any of the patients included in the study. Only 6 patients (40%) presented with epigastralgia, 9 (60%) with nausea and 3 (20%) with vomiting. Conclusions Percutaneous gastric embolisation is an effective and safe procedure to reduce body mass index with a high success rate, well tolerated by obese patients, without major complications, whose results are maintained over time.
- Open Access
- 1 January 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (1) , e012538
Temporal Trends and Contemporary Outcomes After Transcatheter Aortic Valve Replacement With Evolut PRO/PRO+ Self-Expanding Valves: Insights From the NEOPRO/NEOPRO-2 Registries
Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated. Results: In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1–4, 4.1% [2.8–6.3%], 3.7% [2.6–5.3%], 3.3% [2.4–4.9%], 2.9% [2.2–4.3%]; P P =0.038). Overall Valve Academic Research Consortium-3 technical success was 94.1%, with 30-day and 1-year all-cause mortality of 2.4% and 10%, respectively. Throughout the study period, procedures were associated with higher rates of 30-day device success (Q1–4, 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage P =0.023) and early safety (Q1–4, 66.8%, 67.5%, 74.0%, 77.6%; Cochran-Armitage P P =0.023) and residual mild or greater paravalvular leaks (Q1–4, 50.4%, 42.1%, 36.5%, 35.8%; Cochran-Armitage P <0.001). Conclusions: TAVR with Evolut PRO/PRO+ self-expanding valve is safe and effective. Despite the treatment of heavier calcified anatomies, procedural outcomes are improving over time with less need for pacemaker implantation and less significant paravalvular leaks.
- 1 January 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (1) , e012538
Open AccessTemporal Trends and Contemporary Outcomes After Transcatheter Aortic Valve Replacement With Evolut PRO/PRO+ Self-Expanding Valves: Insights From the NEOPRO/NEOPRO-2 Registries
Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated. Results: In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1–4, 4.1% [2.8–6.3%], 3.7% [2.6–5.3%], 3.3% [2.4–4.9%], 2.9% [2.2–4.3%]; P P =0.038). Overall Valve Academic Research Consortium-3 technical success was 94.1%, with 30-day and 1-year all-cause mortality of 2.4% and 10%, respectively. Throughout the study period, procedures were associated with higher rates of 30-day device success (Q1–4, 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage P =0.023) and early safety (Q1–4, 66.8%, 67.5%, 74.0%, 77.6%; Cochran-Armitage P P =0.023) and residual mild or greater paravalvular leaks (Q1–4, 50.4%, 42.1%, 36.5%, 35.8%; Cochran-Armitage P <0.001). Conclusions: TAVR with Evolut PRO/PRO+ self-expanding valve is safe and effective. Despite the treatment of heavier calcified anatomies, procedural outcomes are improving over time with less need for pacemaker implantation and less significant paravalvular leaks.
- 1 May 2022
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 75 (5) , 440-441
Válvula Tendyne facilitada por laceración anterior mitral anterógrada
- 1 May 2022
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 75 (5) , 440-441
Válvula Tendyne facilitada por laceración anterior mitral anterógrada
- 31 January 2022
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 15 (4) , e45-e47
Percutaneous Retrieval of Dislodged Device With Double Biopsy Forceps During Double-Device LAAO
- 31 January 2022
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 15 (4) , e45-e47
Percutaneous Retrieval of Dislodged Device With Double Biopsy Forceps During Double-Device LAAO